Recent Updates
Recently added Catalysts

TERN-601

Phase 2

Overweight or Obesity | Small molecule | Metabolic |Terns Pharmaceuticals, Inc.|Last Updated: Nov 5, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment167
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06854952A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or ObesityPHASE2 COMPLETED 167Mar 1, 2025Sep 1, 2025Nov 5, 2025 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
TERN-601DRUGInvestigational drug
Matching PlaceboOTHERMatching placebo
Unlock Study Design Details